Pregnancy or lactation at the time of study entry; (note: pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to randomization)
Pregnancy or lactation at the time of study entry; (Note: pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential)
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation
Pregnancy or lactation
Current pregnancy or lactation
Pregnancy (independent of outcome) and/or lactation within 1 year prior to the screening mammogram.
Pregnancy, lactation, or breastfeeding women.
Pregnancy (positive serum pregnancy test) or lactation
Pregnancy or lactation.
Current lactation
GENERAL: Pregnancy, lactation, or breastfeeding.
Pregnancy or lactation.
Pregnancy, lactation, or breastfeeding.
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation.
Pregnancy, lactation, or breastfeeding
Pregnancy (positive pregnancy test) or lactation
Pregnancy or lactation.
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy, lactation, or breastfeeding
Patients who are pregnant, are lactation, or breastfeeding
Pregnancy or lactation
Pregnancy or lactation
Patients may not have significant concurrent illness, infection, pregnancy or lactation
Pregnancy and lactation; refusal to use adequate contraception
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Current pregnancy or lactation
TREATMENT: Pregnancy or lactation
Pregnancy (positive pregnancy test) or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy and lactation
Pregnancy or lactation
Pregnancy or lactation at enrollment
Pregnancy or lactation.
Pregnancy or lactation
Pregnancy (positive pregnancy test) or lactation.
Confirmed or suspected pregnancy or lactation
Pregnancy, lactation, or breastfeeding.
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation at the time of study entry (note: pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential)
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation at the time of study entry; (note: pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential)
Pregnancy or lactation
Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential.)
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy (due to unknown effects of this therapy on a fetus) or lactation
Pregnancy or lactation
Pregnancy, lactation, or inability or unwillingness to use medically acceptable forms of contraception if pregnancy is a risk.
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy (positive pregnancy test) or lactation
Pregnancy or lactation.
Pregnancy or lactation at the time of study entry.
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation period
Pregnancy (positive pregnancy test) or lactation
Pregnancy or lactation.
Pregnancy or lactation
Evidence of pregnancy or lactation period
Pregnancy or lactation.
Evidence of pregnancy or lactation period.
Pregnancy or lactation
Pregnancy or lactation.
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy and lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy (positive pregnancy test) or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation at the time of registration
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation
For female participants, current pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation.
Pregnancy, lactation, or breastfeeding
Pregnancy and/or lactation
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation.
Current pregnancy or lactation
Pregnancy (positive pregnancy test) or lactation
Pregnancy or lactation
Pregnancy or lactation.
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy, lactation or breastfeeding
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Lactation
Pregnancy or lactation
Must be > 1 year from pregnancy, lactation or chemotherapy
Lactation or breast feeding.
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation within the prior 6 months
Must be more than 1 year from pregnancy, lactation or chemotherapy
Pregnancy or lactation.
Pregnancy or lactation
Pregnancy or lactation
Greater than 1 year from pregnancy, lactation
Pregnancy or lactation (by history) or positive pregnancy test at screening visit
Have experienced lactation or pregnancy during the previous 12 months
Must be > 1 year from pregnancy, lactation or chemotherapy
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Lactation if the patient is receiving radiation therapy
Pregnancy and lactation
Pregnancy or lactation
Women only: pregnancy or lactation
Pregnancy or lactation
Pregnancy or lactation
Pregnancy, lactation, or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
18. Pregnancy or breastfeeding women.
Pregnancy or active breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding.
Pregnancy or breastfeeding.
Pregnancy, breastfeeding, or intention of becoming pregnant during the study
Pregnancy or breastfeeding patients.
Pregnancy, lactating or breastfeeding women
Pregnancy or breastfeeding
Pregnancy, breastfeeding or possibility of becoming pregnant during the study.
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or active breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding.
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Current pregnancy or breastfeeding
Self-reported pregnancy or breastfeeding or planning a pregnancy within the next two years
Pregnancy or breastfeeding
Pregnancy (positive serum ?-HCG) or breastfeeding.
Pregnancy or breastfeeding.
Pregnancy or breastfeeding;
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding;
Current pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Current pregnancy or breastfeeding
Pregnancy or breastfeeding
DONOR: Pregnancy or breastfeeding
Pregnancy or breastfeeding
Pregnancy or active breastfeeding
Pregnancy or breastfeeding
Self-reported pregnancy or breastfeeding or planning a pregnancy within the next year
Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose.
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 72 hours of start of study treatment
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 2 weeks of study entry
Pregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 72 hours of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 7 days of the start of treatment
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant or breastfeeding; a negative serum pregnancy test is required no more than 14 days before study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative urine pregnancy test within 7 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have two negative pregnancy tests; the first test should be performed within 10-14 days of study entry, and the second test within 24 hours prior to prescribing pomalidomide
Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to randomization, irrespective of the method of contraception used, are excluded from this study; breastfeeding must be discontinued prior to study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 3 days of signing consent
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 72 hours of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 72 hours of study entry
Pregnant or nursing; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Pregnant or breastfeeding; a negative serum pregnancy test is required no more than 7 days before study entry
Pregnant and/or breastfeeding; premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entry (Arm B)
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 7 days of start of study treatment
Pregnant or breastfeeding; a negative serum pregnancy test is required no more than 7 days before study entry
Pregnant and/or breastfeeding; patients of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 7 days of study entry if premenopausal
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 24 hours of study entry
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry and again within 24 hours prior to first treatment.
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine.
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Female patients who are pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entry
Pregnant or breastfeeding, or intending to become pregnant during the study; women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine
Pregnant and/or breastfeeding; patient must have a negative urine pregnancy test within 14 days of study entry
Women of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within 7 days prior to the first dose of study treatment.
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 28 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patients of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative urine pregnancy test within 5 days of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patients that are of childbearing age must have a negative pregnancy test at screening and agree on using contraception during the duration of the study
Pregnant and/or breastfeeding: patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatment
Pregnant or breastfeeding patients; women of childbearing potential must have a documented negative pregnancy test a maximum of 7 days before start of treatment
Pregnant and/or breastfeeding; premenopausal women must have a negative serum or urine pregnancy test within 14 days of study entry
Patient must not be pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 14 days of study entry
Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding women; women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry
Patient must not be pregnant and/or breastfeeding; patient must have a negative urine pregnancy test within seven days of study entry
Pregnant and/or breastfeeding; patient must have a negative serum or urine pregnancy test within 72 hours of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; patient must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days of study entry
Pregnant and/or breastfeeding; female patients must have a negative urine pregnancy test within 14 days of study entry
Pregnancy. If a woman has been confirmed as pregnant she will not be eligible to take part in the trial. If she suspects there is a chance that she may be pregnant, a pregnancy test should be undertaken; however, a pregnancy test for all women of child-bearing potential is not mandatory
Women who are breastfeeding or pregnant as evidenced by a positive pregnancy test within 14 days of first dose.
Pregnancy tests for females of childbearing potential are required; must be serum at screening and the post treatment safety assessment visit; a positive urine pregnancy test must be confirmed by a serum pregnancy test and a pelvic ultrasound (US); a pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do so
Pregnancy or expressed plans to become pregnant within 1 year of the procedure
Women of child-bearing age must obtain a pregnancy test and pregnant or breast-feeding females are excluded
Pregnant or lactating, or intending to become pregnant during the study\r\n* Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug
Males and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry
Is lactating or pregnant as confirmed by pregnancy tests performed within 7 days before enrollment
Pregnant patients do not meet inclusion criteria for radiation therapy.\r\n* Patients who subsequently become pregnant may continue follow up within the protocol, but a negative urine pregnancy test will need to be obtained before additional lesions may be enrolled.
Patients who are pregnant or lactating, plan to get pregnant, or have a positive serum pregnancy test prior to randomization.
Pregnant women; if patients are not status post bilateral salpingo-oopherectomy then pregnancy testing is required
Pregnant or need to breast feed during the study period (negative serum pregnancy test required)
Pregnant or breast-feeding. (While pregnancy is unlikely in view of the disease and previous surgery, subjects whom the investigator considers may be at risk of pregnancy will have a pregnancy [beta-HCG] test and will be using a medically approved contraceptive method).
Sex and reproductive status; a) women of childbearing potential (WOCBP) who are pregnant or breastfeeding; b) women with a positive pregnancy test at enrollment or prior to administration of study medication
Women who are pregnant or breast feeding; a pregnancy test will be administered to women of child bearing potential (per institutional policies) at screening; women must agree to pregnancy tests prior to (up to 1 calendar day) each administration of a radionuclidic agent, including tracer doses, to be considered for this study
Pregnancy status will be obtained at time of consent as is routine for all radiation patients; pregnant women are excluded from this study
Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women; breastfeeding must be discontinued because of unknown but potential risks in the nursing infant
Is pregnant (confirmed by positive serum pregnancy test) or lactating
Pregnant or breast feeding; the agents used in this study include pregnancy category D: known to cause harm to a fetus; females of childbearing potential must have a negative pregnancy test prior to starting therapy
Pregnant or breast feeding women are excluded from participating in this study; WOCBP must have a negative serum pregnancy test within 7 days of the first administration of decitabine
Female patients who are lactating or have a positive serum pregnancy test suggestive of pregnancy and not as a tumor marker during the screening period; if pregnancy is tested positive, treating physician will further investigate if the patient is pregnant or not; treating physician may consider repeating the serum beta-hCG at next follow up visit or refer patient to obstetrical/gynecological (OB/GYN) for further evaluation
Women who are breast-feeding or pregnant as evidenced by positive urine pregnancy test done within 72 hours of first dosing
Women must not be pregnant or breast-feeding\r\n* All female patients of child-bearing potential must have a negative serum pregnancy test within 2 weeks prior to treatment to rule out pregnancy \r\n* Pregnancy testing is not required for post-menopausal or surgically sterilized women
Not pregnant or breastfeeding; a negative pregnancy test is required within 14 days of registration for pre- or perimenopausal (i.e., last menstrual period within one year of registration) women
Women who are pregnant, which includes women with a positive pregnancy test at enrollment or prior to the administration of study medication, or breastfeeding are not allowed on study
Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines
Report of pregnancy, attempting to get pregnant, or actively breast feeding or positive urine pregnancy test (only given to females with child bearing potential)
Pregnant females are excluded; women of childbearing age/menstruating must confirm they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
Pregnant women and women who are breast feeding are excluded; negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period; pregnancy testing will be carried out within two weeks prior to administration of radioiodinated 8H9 in females of childbearing age
Pregnant or breastfeeding - The agents used in this study fall under Pregnancy Category D - Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days of study drug administration
The subject is pregnant, as defined by a presumptive sign of pregnancy such as missed menses or a positive pregnancy test
Pregnant or lactating women; patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment)
Pregnancy: All subjects will have a beta-human chorionic gonadotropin (hCG) serum pregnancy test to rule out pregnancy, a history will also be taken to make certain that recent sexual exposure does not put them at risk for pregnancy; if so a second serum pregnancy test will be done; volunteers will be asked to use barrier contraception during study
Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1
Women who are pregnant or breast feeding; women with a positive pregnancy test on enrollment or prior to study drug administration
Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1.
Pregnant or lactating females; serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days (with a confirmatory urine pregnancy test within 7 days prior to study treatment start)
Women who are breastfeeding or pregnant as evidenced by positive serum pregnancy test
Women who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breast-feeding
Women who are breastfeeding or pregnant as evidenced by positive serum pregnancy test
Pregnant or lactating, or intending to become pregnant during the study: Women who are not postmenopausal (>=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug
Women who are breast feeding or pregnant as evidenced by positive serum pregnancy test.
Negative serum or urine pregnancy test; the pregnancy test result must be obtained prior to the first administration of AUY922 (=< 14 days prior to dosing) in all pre-menopausal women and women < 2 years after the onset of menopause
Pregnant females are excluded; women of childbearing age/menstruating must confirm that they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within 7 days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on study treatment and for 6 months after
Female research participants >= 10 years of age or post-menarchal must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of study enrollment) or breastfeeding
Females of childbearing potential (a female not post-menopausal for at least 12 months or not surgically sterilized) must have a negative beta-human chorionic gonadotropin (HCG) pregnancy =< 7 days prior to day 1 of cycle 1; if the pregnancy test is outside institutional normal range at pretreatment, the subject must have a second pregnancy test; if the second pregnancy test is outside institutional normal range then a gynecology consult is needed to confirm the subject is not pregnant; all patients must agree to use an effective contraceptive method during the course of the study
Patients who are pregnant (positive pregnancy test) or nursing. Use of effective means of contraception (men and women) in subjects of child-bearing potential. To date, no fetal studies in animals or humans have been performed. The possibility of harm to a fetus is likely. Bevacizumab specifically inhibits VEGF, which is responsible for formation of new blood vessels during development, and antibodies can cross the placenta. Therefore, bevacizumab should not be administered to pregnant women.
Pregnant females are excluded; women of childbearing age/menstruating must confirm that they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
Premenopausal and postmenopausal (amenorrheic for less than 12 months) women with either a positive or no pregnancy test (serum or urine) at baseline within 7 days study enrollment; postmenopausal women who are amenorrheic for more than 12 months do not require pregnancy test
Women who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breastfeeding
Women who are pregnant (confirmed by positive pregnancy test) or lactating
Pregnant or breast feeding females (a urine pregnancy test will be obtained in all women of child-bearing age at initial screening prior to study enrollment and administration of chemotherapy)
Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment; if urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* If a pregnancy occurs, the study doctor must be notified; the study doctor should notify the study sponsor as well as Amgen of the pregnancy, discuss any follow-up with the subject (and/or his partner), and ask for information on the pregnancy outcome; the patient should be asked if she wishes to consent to follow up through the Amgen pregnancy surveillance program\r\n* If the female partner is already pregnant when the male subject begins treatment with talimogene laherparepvec, he must refrain from any sort of sexual activity that could expose his partner or the unborn baby to talimogene laherparepvec through semen, or wear a latex condom during sexual activity while receiving treatment with talimogene laherparepvec and for at least 3 months after the last talimogene laherparepvec administration
Women who are pregnant or nursing (pregnancy test to be performed within 24 hours prior to HIFU treatment)
Women who are pregnant or nursing (pregnancy test to be performed within 24 hours prior to HIFU treatment)
Pregnancy or breastfeeding - menstruating females must have a negative pregnancy test prior to study enrollment and agree to repeat pregnancy testing and contraception use per protocol
Pregnancy confirmed by pregnancy test / Lactating women;
Females who are pregnant, lactating, or intend to become pregnant during the participation of the study; childbearing age women who are not on birth control; positive pregnancy test for women of childbearing potential, as defined by intact uterus and ovaries, and no history of menses within the last 12 months; pregnancy test to be performed on the day of enrollment; in cases of women with elevated beta-human chorionic gonadotropin (b-HCG), these candidates will be eligible to participate so long as the level of b-HCG is not consistent with pregnancy and the non-pregnant status is confirmed by a gynecologic examination
Pregnant women will also be excluded (Phase I, part B and Phase II); all female participants who are pregnant or become pregnant over the course of the study are not eligible to participate; women of childbearing potential will be asked to complete a blood pregnancy test (using 1 teaspoon of blood drawn from a vein by needle stick) at their first study visit, and the test must be negative before the woman can continue in the study; women of childbearing potential will be asked to agree to use appropriate contraceptive measures for the duration of the study; participants with medically verified menopausal status (e.g., via tests of ovarian functioning documented in the participants’ medical record) will not be asked to complete a blood pregnancy test
Currently pregnant (assessed by serum pregnancy test)
Women who are pregnant at time of enrollment; pregnancy will be assessed at enrollment using urine pregnancy test
Women will be excluded if they intend to become or are pregnant or lactating; men and women will be required to take active measures to prevent pregnancy while on the study
All pre-menopausal women will require a urine qualitative pregnancy test to exclude pregnancy; pregnant women will be excluded from the study
Not pregnant (confirmed by a pregnancy test)
Women who self-report to be pregnant\r\n* As this is an observational study, we will not be performing a pregnancy test, participants will be asked if they are or are not pregnant
Pregnant or breastfeeding women; positive pregnancy test within 7 days of starting treatment
Patients who are pregnant or breastfeeding; patients will be asked about the possibility of pregnancy; a pregnancy test will be obtained for those patients who have been sexually active without using birth control since their last menstrual period; pregnancy status can be confirmed using any of the following: pregnancy test, prior hysterectomy, tubal ligation, use of intra-uterine device (IUD) or Depo-Provera, or if the woman is beyond childbearing age
Women who are pregnant or nursing; pregnancy will be confirmed by urine test
Patients who are known to be pregnant or who are breastfeeding; patients will be asked about pregnancy status and a pregnancy test will be performed only if there is a high probability of pregnancy
Women who are pregnant or plan a pregnancy within 8 weeks after completion of treatment (only for patients who are going to be randomized to either therapeutic arms)
Subject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.
Currently pregnant or within 3 months post-partum, or unwilling to undergo pregnancy testing or report possible pregnancy promptly
Pregnant women are excluded from this study because CESM uses radiation with the potential for teratogenic or abortifacient effects. This will be defined by a urine pregnancy test prior to the CESM study.
Women who are pregnant or post-partum (within 3 months of delivery); patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta human chorionic gonadotropin (HCG), or best judgement of the investigator; pregnancy testing is not required per protocol to determine study eligibility; women who become pregnant on the ISDO arm via reproductive technology can remain on study; however, data collection will be suspended during pregnancy and 3 months post-partum
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women >= 50 years of age who have not had a menstrual period in the past year; and women who have had a hysterectomy, both ovaries removed, or a tubal ligation; will not be required to have a pregnancy test
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women who are >= 60 years old or who have had a hysterectomy, both ovaries removed, or a tubal ligation will not be required to have a pregnancy test
Pregnancy at any point during the study period OR considering pregnancy during the study period
Women on study must be neither pregnant nor nursing nor expected to become pregnant during therapy; for premenopausal women, negative pregnancy test within 14 days of RT is required
The patient is pregnant as confirmed by urine or serum pregnancy testing,
Patients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to each set of multi-tracer PET scans in female patients that are not postmenopausal or surgically sterile
Pregnant or lactating women: pregnant women are excluded from this study because the effects of [18F] FAZA in pregnancy are not known. A urine or serum pregnancy test will be performed before accrual after informed consent is obtained.
Pregnant women or breastfeeding\r\n* Potential subjects will be asked if they are pregnant; verbal confirmation of pregnancy will be sufficient
Patients who are currently pregnant or breast feeding; a pregnancy test within 72 hours of the first PET/MRI will be performed
Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.
Pregnancy; regular clinical practice already excludes pregnant patients from gadolinium contrast; the current clinical practice will be applied - patients will be verbally screened and asked if they think they could be pregnant; if the answer is yes, then the patient will be excluded from the study; if the patient is uncertain about the pregnancy status, she will be given an option to undergo a pregnancy test or not participate in the study altogether; patients who self-report that they are not pregnant will be allowed to participate in the study; this procedure is based on current department policy guidelines
Patients who are pregnant or lactating or who suspect they might be pregnant are not eligible; a serum pregnancy tests will be obtained 24-48 hours prior to the initial PET scan in female patients who are not postmenopausal or surgically sterile
Patients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to each set of multi-tracer PET scans in female patients that are not postmenopausal or surgically sterile
Women who are pregnant, as well as those women who are breastfeeding, will be excluded from this study; as part of their routine preoperative testing, all women of child bearing age receive a pregnancy test; the research staff will follow up on these results in order to determine eligibility; women who have had a hysterectomy or have not had menses for > 24 months will not be required to undergo a pregnancy test; breastfeeding women will be excluded from this study
Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded
Patients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to the baseline and subsequent multi-tracer PET scans in female patients that are not postmenopausal or surgically sterile
Pregnant or lactating female, a serum pregnancy test will be performed within 2 weeks or less before the date of the FCH PET/CT scan in all women capable of becoming pregnant
Females who are pregnant as confirmed by a positive serum or urine pregnancy test or are breastfeeding.
Breastfeeding or pregnant; serum pregnancy test will be conducted
Patients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to the baseline and subsequent multi-tracer PET scans in female patients that are not postmenopausal or surgically sterile
Female patients undergoing optional 18F-MISO-PET scan cannot be pregnant or nursing, as confirmed by serum pregnancy test if the patient is a woman of child-bearing potential; females of child-bearing potential are defined according to Food and Drug Administration (FDA) guidelines as women capable of becoming pregnant, including women on oral injectable or mechanical contraception, women who are single, women whose husbands have been vasectomized, or women whose husbands have received or are utilizing mechanical contraceptive devices; if the result of the pregnancy test is positive, the patient (female) will be withdrawn from the study prior to administration of study treatment
Pregnant or breastfeeding - if the subject is female, the investigator will provide a urine pregnancy test at no cost to the subject; the subject will take the pregnancy test immediately before participating in this study
Women who are pregnant or lactating, if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus
Pregnant, planning a pregnancy or breast feeding during the study
Pregnant, lactating, or planning to become pregnant during the study and up to 3 months after last dose of study drug
Woman of childbearing potential that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for 3 months after last dose of talimogene laherparepvec
Females who are pregnant, breast-feeding, or planning to become pregnant within 3 months after the last dose of study drug and males who plan to father a child while enrolled in this study or within 5 months after the last dose of study drug
Pregnant, planning a pregnancy, or breast feeding
Patients who are breastfeeding, pregnant, or planning to become pregnant from the time of informed consent until 6 months after the final study dose is administered
If female, is pregnant, breastfeeding, or planning to become pregnant.
Female subjects who are pregnant or breastfeeding or planning to become pregnant or breastfeed, or of childbearing potential unwilling to use an effective method of contraception while receiving, and for an additional 48 hours after the last dose of blinatumomab.
A woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 5 months after the last dose of study drug
Patients who are pregnant or lactating or who are planning to become pregnant during the course of the study are excluded.
If female, is pregnant, breastfeeding, or planning to become pregnant.
Women planning to become pregnant while on study through 1 week after receiving the last dose of study drug
Pregnant or planning to become pregnant during period of study participation
Subject who is pregnant (as confirmed by pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding; and
Pregnant, breast feeding, or planning to become pregnant
Females who are pregnant or breastfeeding or planning to become pregnant within 90 days after their last anticipated dose of BCV
A woman who is pregnant or breast-feeding, or a woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study agent
Female subjects who are pregnant, are planning on becoming pregnant, or are currently breastfeeding.
Breast-feeding at screening or planning to become pregnant during the course of therapy
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Female subject is pregnant or breast-feeding, or planning to become pregnant or male subject is planning to father a child within the projected duration of the trial, starting with the pre-screening or screening visit, during study treatment and through 3 months after the last dose of talimogene laherparepvec or 4 months after the last dose of pembrolizumab, whichever is later
Women who are pregnant or breast-feeding currently or are planning to do so during or up to 3 months after the end of protocol therapy.
Subject is pregnant or breast feeding, or planning to become pregnant/breastfeed while on study through 5 months after the end of treatment
Females who are pregnant, breastfeeding, or planning a pregnancy during the treatment period or within 12 months after the last infusion of study drug.
Breast-feeding at screening or planning to become pregnant during the course of therapy
Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment
Pregnancy, breast-feeding or planning to become pregnant
Female subjects who are pregnant or planning to become pregnant during the course of SABR
Women who are planning to become pregnant or breast feed during the trial
Patient is pregnant, lactating, or planning on being pregnant within the next 6 months
Pregnant or lactating or planning pregnancy during treatment period.
221 Females planning to become pregnant while on study through 110 days after receiving the last dose of study drug.
Female of child bearing potential who is pregnant, is planning to become pregnant, or is breast feeding; or male who is sexually active with a female of child bearing potential who is planning to become pregnant.
Female patients who are pregnant, breast-feeding, or planning to become pregnant
Pregnant, planning to become pregnant, or breast feeding.
Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 4 months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while enrolled in this study or within 4 months after the last dose of any component of the treatment regimen
Pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Pregnant, planning to become pregnant, or nursing
Pregnant, planning to become pregnant, or nursing
Pregnancy, or planning to become pregnant
Women planning to become pregnant or who are lactating/breastfeeding while on study through 4 months after receiving the last dose of study drug.
Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed while receiving blinatumomab and for an additional 48 hours after the last treatment dose of blinatumomab.
Be pregnant, planning a pregnancy, or breastfeeding
Patients planning to take a vacation for 7 or more consecutive days during the course of the study.
Currently pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment
Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;
Is pregnant, breastfeeding, or planning a pregnancy
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec
Subjects who are pregnant or lactating or who are planning to become pregnant during the course of the study are excluded.
Patients who are currently pregnant, planning to become pregnant, or breast-feeding
Patient is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Currently pregnant or nursing, or planning pregnancy (in the period up to 6 months) following the index procedure(s),
Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment.
The participant is pregnant, breastfeeding, or planning to become pregnant or father a child
Pregnant, nursing or planning to become pregnant
Subject is currently pregnant or breastfeeding, or is planning to become pregnant during the study
Patient is a female who is pregnant, lactating, or is planning a pregnancy during study participation, or in the follow-up period.
Pregnant, breastfeeding, or planning to become pregnant during the study;
Pregnant or planning to become pregnant
Pregnancy or planning to become pregnant
Is pregnant, breastfeeding, or planning a pregnancy
Pregnant, lactating or planning to become pregnant
Females in the study must not be pregnant or breast feeding and not planning to become pregnant or breast feed for the duration of the study, and for at least three months after study completion
Women who are lactating/breastfeeding or planning to become pregnant during the duration of the study
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product.
Female patients who are pregnant or breast-feeding are not eligible; NOTE: A woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study agent should likewise not be considered for this study
Female subjects who are pregnant, or breastfeeding, or planning to become pregnant. Male subjects who plan to father a child while enrolled in this protocol.
Subject is pregnant, nursing, or planning to get pregnant during study duration.
Those who are currently pregnant, have been pregnant within the last 6 months, or are planning to become pregnant in the next 6 months.
Patient is pregnant, breastfeeding, has given birth within the last 3 months or planning pregnancy within the next 12 months; if participant becomes pregnant during the course of the study, she will be removed from further participation
Not currently pregnant or planning to become pregnant throughout the duration of cancer treatment
Negative se rum pregnancy test and not planning to be pregnant in the next 3 months
A positive pregnancy test, currently pregnant or planning to become pregnant in the next three months
Currently pregnant, nursing or planning to become pregnant
Currently pregnant or planning to become pregnant
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment
Women who are pregnant or breastfeeding or planning to become pregnant or breastfeed during the period of treatment and for 112 days following the last dose of sotatercept
Self-report that they are not pregnant or planning to become pregnant in the next four months
Pregnant or planning to become pregnant during the course of the study
Not pregnant or planning on becoming pregnant
Patient is a woman with a positive serum pregnancy test at screening, is pregnant, breast-feeding, or is planning to conceive children within the projected duration of the study treatment
Are planning to conceive or are currently pregnant or lactating
Women who are breastfeeding, pregnant, or planning pregnancy within the next year
Pregnant or planning to become pregnant within the next year
Patients who are pregnant, planning pregnancy, or breast feeding
Being pregnant or planning on becoming pregnant within the next year
Planning to move from the area within the next year
Women who are pregnant or lactating, or planning pregnancy while enrolled in the study or for 7 months after the last dose of the study drug
Pregnant, planning to become pregnant starting from 28 days prior to receiving CC-486 throughout your participation in the study, and for at least 90 days following your last dose of study treatment, or breast-feeding females
Women who are pregnant, planning pregnancy within the next year, or lactating/breastfeeding
Female planning to become pregnant or planning to discontinue contraceptive precautions before Month 3 (i.e., 2 months after the last dose of study vaccine/placebo).
A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose.
Subjects who have contraindications for receiving Y-90 therapy and any routine procedures and imaging associated with Y-90 therapy, including subjects who are pregnant or are planning to become pregnant, will not be eligible to participate in this study. Female subjects who are of childbearing potential should inform her treating physician should she become pregnant at any time during the course of the study
Women who are pregnant or planning to become pregnant during the trial
Patients who are pregnant, breast-feeding or are planning to become pregnant during the study duration
Pregnant or breastfeeding, or planning to become pregnant.
For female participants: being pregnant or breastfeeding, or planning to become pregnant, by self-report
Pregnancy and contraception: Subjects who are pregnant, breast-feeding or planning to conceive within 30 days are not eligible
Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study.
not pregnant, breastfeeding, or planning to become pregnant
Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
Female subject who is pregnant or breastfeeding, or planning to become pregnant within 30 days after ending treatment
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
Pregnancy or breast-feeding
the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
Pregnancy, breast feeding, or unwillingness to use effective contraception during the study.
Pregnancy or breast-feeding
Pregnancy or breast-feeding
Pregnancy or breast feeding.
Pregnancy or breast-feeding.
Pregnancy or breast feeding.
Pregnancy or active breast feeding
Pregnancy or breast feeding.
Pregnancy and breast feeding.
Pregnancy or breast-feeding women
Pregnancy or breast feeding.
Pregnancy or mothers who are breast feeding.
Pregnancy or breast-feeding within 30 days prior to enrollment
Pregnancy and breast feeding
Pregnancy or breast-feeding
Pregnancy or breast-feeding
Pregnancy or breast-feeding at time of Screening and throughout the study.
Pregnancy or breast-feeding
Pregnancy or breast feeding female
Pregnancy or breast feeding.
Pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast-feeding
Pregnancy or breast-feeding
Pregnancy or unwillingness to stop breast-feeding
Known pregnancy or breast feeding
Known pregnancy or breast-feeding
Pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast feeding.
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy, breast feeding, or unwillingness to use effective contraception during the study.
Pregnancy, breast feeding, or unwillingness to use effective contraception during the study
Pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
For women of childbearing potential, no pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding mother
Pregnancy or breast feeding.
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy and breast feeding
Pregnancy or breast-feeding
Pregnancy or breast-feeding women
Pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast-feeding women
Pregnant (positive serum pregnancy test) or breast feeding
Pregnancy or breast-feeding.
Pregnancy or breast feeding.
Pregnancy or breast feeding
Pregnancy (positive serum or urine pregnancy test) or breast feeding
Pregnant (positive pregnancy test) or breast feeding
Pregnancy or breast-feeding
Pregnancy, breast feeding, or unwillingness to use effective contraception during the study.
Pregnancy or breast-feeding.
Pregnancy or breast feeding
Pregnant (positive serum pregnancy test) or breast feeding
Pregnancy or breast-feeding
Pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast-feeding.
Pregnancy/Breast feeding
Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
Pregnancy or breast-feeding.
Pregnancy or breast-feeding.
Pregnancy or breast-feeding
Pregnancy or breast-feeding.
Pregnancy or breast-feeding; radiation therapy to the pelvis is contraindicated during any stage of pregnancy
Pregnancy (positive serum or urine pregnancy test) or breast feeding;
Pregnancy or breast-feeding
Pregnancy or breast feeding
Pregnancy or breast feeding.
Pregnancy or breast feeding
Current pregnancy and breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Pregnancy or breast feeding
Women must be one year from pregnancy and breast-feeding
Participants who have a positive pregnancy test, are pregnant, or breast feeding
Pregnancy or breast feeding
Pregnancy, breast feeding, or planning pregnancy within 1 year
Pregnancy or breast-feeding.
Known pregnancy or breast-feeding
Breast feeding / pregnancy
Known pregnancy or breast-feeding
Breast feeding/pregnancy
Pregnancy or lactating with the intent of breast feeding
Known pregnancy or breast-feeding
Positive urine pregnancy test or currently breast-feeding
Positive urine pregnancy test or currently breast feeding
Pregnancy or breast feeding
Pregnancy or breast-feeding
pregnancy or breast-feeding
the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
Women must not be breastfeeding.
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding.
Women must not be breastfeeding
Women who are breastfeeding
Women who are breastfeeding.
Women must not be breastfeeding.
Participants who are women must not be breastfeeding
Women must not be breastfeeding.
Women must not be breastfeeding.
Women must not be breastfeeding.
Women must not be breastfeeding.
Women who are breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women who are breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Breastfeeding women.
Women must not be breastfeeding
Women must not be breastfeeding
Women who are breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women who are breastfeeding
Women who are breastfeeding
Women must not be breastfeeding
Breastfeeding women.
Women who are breastfeeding
Women must not be breastfeeding.
Women who are lactating or breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding at the time of study registration
Women must not be breastfeeding
Women must not be breastfeeding
Women who are breastfeeding.
Women must not be breastfeeding.
Women who are breastfeeding
Women who are breastfeeding
Women who are breastfeeding
Women who are breastfeeding
Women must not be breastfeeding
Women who are breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding
Women must not be breastfeeding.
Women who are breastfeeding
Women must not be breastfeeding
Women who are breastfeeding
Breastfeeding women
Women who are breastfeeding are not eligible for this study.
Breastfeeding women
Women who are breastfeeding
Women must not be breastfeeding
Women who are breastfeeding
Women must not be breastfeeding
Woman who is pregnant or lactating or has a positive pregnancy test at screening. If a woman has a positive pregnancy test, further evaluation may be conducted to rule out ongoing pregnancy to allow the patient to be eligible
Female subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment.
Female patients who are nursing or have a positive pregnancy test during screening are not eligible
A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study treatment.
Has a positive pregnancy test within 72 hours before the first dose of study therapy
Positive serum pregnancy test
A positive pregnancy test will exclude patients from the study in addition to excluding them from receiving standard therapy
Women with a positive pregnancy test
DONOR: Females with a positive pregnancy test
A WOCBP who has a positive serum pregnancy test within 72 hours prior to enrollment on study
WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment
Women with a positive pregnancy test at enrollment or prior to administration of study medication.
Women with a positive pregnancy test
Women with a positive pregnancy test or lactating.
Participants with borderline pregnancy tests at Screening must have a serum pregnancy test ? 3 days later to document continued lack of a positive result.
Women with a positive pregnancy test on enrollment or prior to investigational product administration
Positive pregnancy test for women of childbearing age
Women with a positive pregnancy test on enrollment or prior to investigational product administration
Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test
Women with a positive pregnancy test.
Women with a positive pregnancy test
Positive pregnancy test in a female
Positive serum pregnancy test
Positive serum pregnancy test
Positive pregnancy test for women of childbearing age
Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test
220 Females with a positive pregnancy test.
WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment
Women with a positive pregnancy test on enrollment or prior to investigational product administration
DONOR: Females with a positive pregnancy test
Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test
Women with a positive pregnancy test on enrollment or prior to investigational product administration
Known pregnancy, nursing women or positive pregnancy test
Women with a positive pregnancy test at enrollment or prior to administration of study medication
Positive pregnancy test in a female
Positive pregnancy test
Women with a positive pregnancy test on enrollment or prior to investigational product administration
A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study treatment
Pregnant (positive pregnancy test)
Women with a positive pregnancy test
Women with a positive pregnancy test on enrollment or before investigational product administration
Women with a positive pregnancy test
Positive pregnancy test.
Woman who is pregnant or lactating or has a positive pregnancy test at screening. If a woman has a positive pregnancy test, further evaluation may be conducted to rule out ongoing pregnancy to allow the patient to be eligible.
Pregnant (positive pregnancy test) or lactating
Inadequate organ functions, positive pregnancy test.
Female subjects who have positive serum pregnancy test taken within 14 days of study treatment
Women with a positive pregnancy test on enrollment or prior to investigational product administration
Women with a positive pregnancy test at study entry.
Positive pregnancy test on day of surgery
Positive pregnancy test or breastfeeding of patient or donor (women of childbearing age only)
Positive pregnancy test
Positive pregnancy test (women of childbearing age only)
Positive pregnancy test or nursing (women of childbearing age only)
Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test
Positive pregnancy test
Pregnancy, or positive pregnancy test
Currently known to be pregnant; (Note that urine pregnancy tests will be performed prior to the DXA and pQCT studies; positive pregnancy test at that time would preclude participation; a positive pregnancy test will be immediately reported to the patient’s primary oncology provider)
Positive serum pregnancy test in WOCBP
Positive pregnancy test
Positive serum pregnancy test for females
Positive Hemoglobin-Solubility (e.g., SickleDex™ or equivalent) test.
Pregnancy, or positive pregnancy test